"Further, the paracetamol API industry is expected to clock a 5-7% CAGR between FY23 and FY27," said analysts, while suggesting investors can hold the stock for the long term if they wish to.
Considering the upper price band of Rs 140, the stock is likely to debut with a premium of 16%. The IPO received a healthy subscription of 29.7 times at the close